CISON PR Newswire – RLF-100™ therapy associated with a 9-fold increased probability of survival and recovery from respiratory failure in an open-label, prospective study– Top-line data from randomized, placebo-controlled Phase 2b/3 trial expected this quarter GENEVA and RADNOR, Pa., Oct. 13, 2020 /PRNewswire/ — RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF) and NeuroRx, Inc., today announced topline results from 45 […]
By Lia Eustachewich, NY Post The race is on to find a treatment that works to quash the coronavirus — as the deadly disease continues to spread across the globe. Here’s a list of the most promising treatments and potential vaccines for SARS-CoV-2, the virus that causes COVID-19. Remdesivir The experimental antiviral drug, made by Gilead Sciences, was […]
CISON PR Newswire Emergency Use Authorization request targets the same population as is currently permitted under FDA Expanded Access Protocol RADNOR, Pa., Sept. 23, 2020 /PRNewswire/ — NeuroRx, Inc. has submitted a request for an Emergency Use Authorization (EUA) with the US FDA for the use of RLF-100™ aviptadil in patients who are receiving intensive care […]
By Tova Cohen; Reuters TEL AVIV (Reuters) – Critically ill COVID-19 patients recovered rapidly from respiratory failure after three days of treatment with RLF-100, a therapy granted fast-track designation in the United States, two drug companies said on Sunday. Geneva-based Relief Therapeutics Holdings AG RFLB.S has a patent for RLF-100, or aviptadil, a synthetic form of […]
With resurgent COVID-19, enrollment has accelerated in Miami, Houston, and Irvine.
A drug that mimics a peptide produced by the bowel has been fast-tracked by the Food and Drug Administration to treat COVID-19 lung inflammation, NeuroRx Inc. announced Wednesday. The drug protects cells believed to act as a gateway for the coronavirus to attack the lungs.
Fast Track Designation of RLF-100 for the treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome associated with COVID-19 underscores the urgent need for new treatment options for these patients.
University of Miami Health System
Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in Critical COVID-19.